lymphoma: Cancer and Leukemia Group B study 19801 refractory T-lineage acute lymphoblastic leukemia or lymphoblastic Nelarabine induces complete remissions in adults with relapsed or

[1]  M. Schmid,et al.  Compound GW506U78 Has High Single-Drug Activity and Good Feasibility in Heavily Pretreated Relapsed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL) and Offers the Option for Cure with Stem Cell Transplantation (SCT). , 2005 .

[2]  J. Kurtzberg,et al.  Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Kurtzberg,et al.  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  F. Mandelli,et al.  A single high dose of idarubicin combined with high‐dose ARA‐C for treatment of first relapse in childhood ‘high‐risk’ acute lymphoblastic leukaemia: a study of the AIEOP group , 2002, British journal of haematology.

[5]  J. Kurtzberg,et al.  Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. , 2000, Journal of Clinical Oncology.

[6]  Terry L. Smith,et al.  Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.

[7]  J. Kurtzberg,et al.  Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Mandelli,et al.  ALL R‐87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse , 1997, British journal of haematology.

[9]  F. Mandelli,et al.  Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R‐87 protocol , 1997, British journal of haematology.

[10]  J. Wilson,et al.  2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. , 1995, Cancer research.

[11]  J. Kurtzberg,et al.  PHARMACOLOGIC PURGING OF MALIGNANT T CELLS FROM HUMAN BONE MARROW USING 9‐β‐D‐ARABINOFURANOSYLGUANINE , 1991, Transplantation.

[12]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Mitchell,et al.  Differential metabolism of 9-β-D-arabinofuranosylguanine in human leukemic cells , 1989 .

[14]  A. Fridland,et al.  Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. , 1985, Cancer research.

[15]  P. Daddona,et al.  Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. , 1985, Cancer research.

[16]  D. Martin,et al.  Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. , 1984, The Journal of clinical investigation.

[17]  E. Gelfand,et al.  Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. , 1983, Blood.

[18]  G. Koszalka,et al.  Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. , 1981, Biochemistry.

[19]  R. Larson,et al.  Treatment of adult acute lymphoblastic leukemia. , 1997, Seminars in oncology.

[20]  E. Gelfand,et al.  Sensitivity of T-leukemic cells to deoxyguanosine and arabinosyl guanine. , 1984, Advances in experimental medicine and biology.

[21]  L. Goodman,et al.  SYNTHESIS OF 9-BETA-D-ARABINOFURANOSYLGUANINE. , 1964, Biochemistry.